Patents by Inventor Henry A. Miller

Henry A. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimicrobial Compounds
    Publication number: 20100081650
    Abstract: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 1, 2010
    Inventors: Jeffrey Michael Axten, Robert A. Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Antibacterial agents
    Patent number: 7655648
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7648980
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7648984
    Abstract: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Jeffrey Michael Axten, Mark Andrew Seefeld
  • Antibacterial compounds
    Patent number: 7622481
    Abstract: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: November 24, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jeffrey Michael Axten, Robert A Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Antibacterial agents
    Patent number: 7618959
    Abstract: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: November 17, 2009
    Assignee: SmithKlineBeecham Corp
    Inventors: Jeffrey Michael Axten, Timothy Francis Gallagher, William Henry Miller, Mark Andrew Seefeld
  • N-substituted glycine derivatives: hydroxylase inhibitors
    Patent number: 7608621
    Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: October 27, 2009
    Assignee: SmithKline Beecham, Corp.
    Inventors: Antony N. Shaw, Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Michael N. Zimmerman
  • Antibacterial agents
    Patent number: 7605169
    Abstract: Napthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: October 20, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7592334
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: September 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial Agents
    Publication number: 20090181955
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: March 26, 2009
    Publication date: July 16, 2009
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial agents
    Patent number: 7511035
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: March 31, 2009
    Assignee: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • TOY PROJECTILE LAUNCHER
    Publication number: 20090071455
    Abstract: The present invention is a toy projectile launcher in the form of a role play accessory such as a belt. The belt assembly includes a strap, a launcher housing, and projectiles stored on the belt strap. The belt strap feeds through the launcher housing so that projectiles may be launched from the strap. In one embodiment the launcher is hand-held, and includes a handle which serves both as a means for holding the launcher during operation and as a power switch for the launcher. Projectiles may be discharged singly from the launcher or continuously in a rapid-fire mode.
    Type: Application
    Filed: September 15, 2007
    Publication date: March 19, 2009
    Inventors: Brandon C. Sopinsky, Binh Luong, Steed Sun, Peter Fan, Henry Miller
  • Compounds
    Patent number: 7498326
    Abstract: Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. The piperidine derivatives include compounds of formula (I): wherein RA, AB, n, R3, R2 and R4 are defined herein. For example, RA is an optionally substituted bicyclic carbocyclic or heterocyclic ring system, and R4 is a group U-R5 in which R5 is an optionally substituted bicyclic heterocyclic ring system as defined herein (e.g. optionally substituted pyrido [3,2, -b][1,4] thiazin-yl).
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: March 3, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jeffrey Michael Axten, Robert A Daines, David Thomas Davies, Timothy Francis Gallagher, Graham Elgin Jones, William Henry Miller, Neil David Pearson, Israil Pendrak
  • Antibacterial Agents
    Publication number: 20090054418
    Abstract: 2H-chromen-2-one derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 26, 2009
    Inventors: William Henry Miller, Alan T. Price
  • Treatment Method
    Publication number: 20080293691
    Abstract: The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.
    Type: Application
    Filed: November 29, 2006
    Publication date: November 27, 2008
    Inventors: Richard Anthony Brigandi, Mark Levick, William Henry Miller
  • N-Substituted Glycine Derivatives: Hydroxylase Inhibitors
    Publication number: 20080214549
    Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: January 11, 2008
    Publication date: September 4, 2008
    Inventors: Antony N. SHAW, Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Michael N. Zimmerman
  • Antibacterial Agents
    Publication number: 20080194547
    Abstract: Naphthalene, quinoline, quinoaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: July 8, 2005
    Publication date: August 14, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial Agents
    Publication number: 20080146551
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 19, 2008
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial Agents
    Publication number: 20080139539
    Abstract: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 12, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld
  • Antibacterial Agents
    Publication number: 20080139540
    Abstract: Naphthyridine and related derivatives useful in the treatment of bacterial infections, particularly humans, are disclosed herein.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 12, 2008
    Applicant: Glaxo Group Limited
    Inventors: William Henry Miller, Meagan B. Rouse, Mark Andrew Seefeld